WAT · Waters Corp /De/

Brings Xevo™ TQ Absolute XR Mass Spectrometer's industry-leading tandem quadrupole MS sensitivity to clinical applications across women's health, cancer assessment, and toxicology. Offers 5x greater sensitivity vs. in-class instruments with lower detection limits in smaller sample volumes, introducing a step-change in analytical performance for complex biological matrices. Up to six-fold increase in robustness with StepWave™ XR Ion Guide vs. Xevo TQ Absolute MS, advancing laboratory productivity and performance consistency. MILFORD, Mass. , July 27, 2026 /PRNewswire/ -- The Association for Diagnostics & Laboratory Medicine (ADLM) 2026 Annual Meeting — Waters Corporation (NYSE: WAT) today announced the launch of the Xevo TQ Absolute XR IVD Mass Spectrometer, expanding its MassTrak™ IVD System portfolio of LC-MS/MS Systems with a solution that combines class-leading sensitivity and enhanced robustness for clinical applications. The new system builds on the industry-renowned step-change performance of the Xevo TQ Absolute IVD Mass Spectrometer, which established the benchmark for sensitivity among IVD-compliant tandem quadrupole mass spectrometers. 1 Developed for routine laboratory testing requiring IVD-compliant systems, the Xevo TQ Absolute XR IVD System delivers exceptional trace-level analytical performance in complex biological matrices. With up to five times greater sensitivity than other instruments in its class, 1 the system enables lower limits of detection and reliable quantification of challenging analytes from smaller sample volumes. This enhanced sensitivity is critical for applications requiring accurate measurement at very low concentrations, such as low-level estradiol testing for women's health and hormone-related cancer assessment, 2 and hair toxicology 3 for detecting drugs of abuse and documenting long-term exposure. "Waters' IVD Systems provide clinical diagnostic laboratories with highly precise and flexible solutions that help clinicians make informed decisions when every test matters," said Jianqing Bennett, Senior Vice President, Waters Advanced Diagnostics, Waters Corporation. "With the introduction of the Xevo TQ Absolute XR IVD System, Waters is delivering a new standard of sensitivity and robustness that can significantly reduce downtime and improve laboratory productivity. Waters is uniquely positioned to help clinical laboratories develop reliable methods for complex analytes and expand their testing capabilities to meet growing demand across women's health, cancer assessment, and toxicology applications." Featuring the new StepWave™ XR Ion Guide, the Xevo TQ Absolute XR IVD System delivers improved robustness, enabling ion ratio consistency for up to six times longer compared with the Xevo TQ Absolute IVD System. 4 This advancement gives laboratories greater confidence in consistent performance when analyzing complex clinical samples containing phospholipids, salts, and other matrix components. "Having the Xevo TQ Absolute XR IVD Systems in our laboratory is a major advancement for the company," said James Nutt, Head of Laboratory Operations, Cansford Laboratories. "The systems strengthen our analytical reliability, have the potential to greatly expand our substance testing capabilities, and improve operational efficiency. They deliver better signal stability and improved sensitivity, which is especially important when working close to decision cut-offs in complex matrices such as human hair. This gives us greater confidence in our results and provides additional assurance when measuring analytes at very low concentrations." This new MassTrak LC-MS/MS IVD System includes the ACQUITY™ UPLC I-Class PLUS System with the Xevo TQ Absolute XR IVD Mass Spectrometer. The ACQUITY UPLC I-Class PLUS System is designed to deliver fast, accurate sample analysis that enhances mass spectrometer performance and simplifies the characterization of complex samples. Together, the integrated system delivers indu

MILFORD, Mass. , July 2, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) will hold its Q2 2026 financial results conference call on Tuesday, August 4, 2026, at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters' Investor Relations website at https://ir.waters.com . A replay of the webcast will also be available until at least September 1, 2026, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~16,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide. For more information, please visit www.waters.com/about . Caspar Tudor, Head of Investor Relations [email protected] View original content: https://www.prnewswire.com/news-releases/waters-corporation-schedules-second-quarter-2026-earnings-conference-call-302816469.html SOURCE Waters Corporation

IMU's AI platform unlocks unprecedented immune insights for cancer and other diseases, measuring 100M+ data points from a single blood sample, analyzed in real time. Waters Biosciences' technologies, including BD FACSDiscover™ and BD Rhapsody™ Instruments, will be used with IMU's AI analytics in research to deliver deeper, population-level disease insights. Partnership supports IMU's expansion of its world-leading immune dataset through large-scale studies, establishing a new standard for immune profiling. MILFORD, Mass. , June 24, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) and IMU Biosciences, a biotechnology company decoding the immune system to pioneer a paradigm shift in how we understand, diagnose, and treat disease, today announced a strategic partnership to accelerate the development of IMU's next-generation AI-powered High Definition (HD) Immunology platform. The partnership brings together Waters Biosciences' advanced flow cytometry and single-cell technologies, 1 including BD FACSDiscover Cell Analyzers, BD flow cytometry reagents with BD Horizon™ Real Dyes, BD Rhapsody Instruments, and BD OMICS-One™ WTA Next Assay and Protein Panels, with IMU's HD analysis and proprietary AI and machine learning analytics, that can reproducibly characterize the immune system in real time, to turn complex immune data into insights at scale across discovery, translational, and clinical research applications. IMU measures the immune system in unprecedented detail, delivering more than 100 million data points from a single blood sample, 2 combining HD multiomic analysis with machine learning analytics. IMU is building the world's largest immune dataset, 3 with unrivaled access to patient samples and population-wide clinical data, establishing a universal standard for immune profiling. "Waters Biosciences was the clear partner to help IMU Biosciences scale our HD Immunology platform to the level required for true population-wide immune mapping, given their longstanding leadership in high-throughput flow cytometry and single-cell technologies," said John Baker, Ph.D., Chief Executive Officer, IMU Biosciences. "Our world-leading immune dataset and proprietary AI analytics will unlock the potential of Waters' best-in-class analytical instruments, accelerating our work to decode the immune system and power the next generation of precision medicine." Steve Conly, Senior Vice President, Waters Biosciences, Waters Corporation added, "By partnering with IMU Biosciences, we are helping to build the most detailed picture of the human immune system ever assembled at clinical scale. Together, our companies' cutting-edge technologies across instruments, reagents, and informatics will help advance immune profiling into a standardized, universally accessible clinical tool that can be used across the continuum of care for cancer and other diseases, supporting smarter, faster drug development." The companies intend to pursue additional studies in translational research for novel biomarker discovery to enable clinical applications in flow cytometry. Waters Biosciences and IMU Biosciences presented data at the annual meeting of the International Society for the Advancement of Cytometry (CYTO 2026), demonstrating system-level immune profiling on the BD FACSDiscover A8 Cell Analyzer with a 58-color spectral panel using BD reagents, and i

Integrates heat flow, evolved gas, and electrochemical analysis in a single experiment, enabling earlier insights into thermal runaway. Unique whole-cell design eliminates cell teardown, reducing sample preparation time by >90%. Industry-leading Coin Cell DSC temperature range from –80 °C to 600 °C, aiding battery development and QA/QC. MILFORD, Mass. , June 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced the launch of the Waters TA Instruments™ Coin Cell Differential Scanning Calorimeter (DSC), designed to transform battery safety testing. Purpose-built for battery scientists, the Coin Cell DSC enables direct testing of fully assembled coin cells, eliminating time-intensive preparation steps while delivering faster, more descriptive safety and performance insights. The Coin Cell DSC is the only commercially available DSC 1 that provides multidimensional data capture and enables researchers to collect whole-cell thermal data while simultaneously measuring evolved gas and electrochemical performance. By incorporating voltage monitoring and charge/discharge capability, researchers can directly correlate thermal and electrochemical behavior enabling earlier insights into thermal runaway and battery failure. It can also be coupled with MS, Fourier Transform Infrared Spectroscopy (FTIR), or Gas Chromatography-Mass Spectrometry (GC-MS) to enable direct analysis of off-gas composition. "The Coin Cell DSC represents a significant advancement in battery thermal analysis," said Yu Cheng, Vice President, Research and Development and Product Solutions, Materials Sciences, Waters Corporation. "Simultaneously capturing thermal, evolved gas, and electrochemical data is not only faster, but also correlates data from the same sample for more exacting insights earlier in development. With its broad temperature range and streamlined workflows, the system is designed to reduce experimental complexity while outperforming current approaches." The Coin Cell DSC introduces a unique capsule design that eliminates the highly time-consuming need for cell teardown, reducing the average sample preparation time by more than 90%. 2 This approach preserves sample integrity while significantly accelerating data generation. The new system redefines thermal analysis by integrating advanced temperature performance, efficient workflows, and multidimensional data capture into a single platform. With an industry-leading –80 °C to 600 °C range, 3, 4 the Coin Cell DSC enables comprehensive analysis of low- and high-temperature behavior, expanding future applications in development and QA/QC. "The battery industry has long needed a solution that bridges the gap between materials thermal analysis and ful

新闻摘要： 将热流、逸出气体和电化学分析集成于单次实验中，实现对热失控现象的早期洞察。 独特的全电池测试设计免去了拆解电池的步骤，将样品制备时间缩短了90%以上。 行业翘楚的Coin Cell DSC检测温度覆盖–80到600 ℃，有助于电池开发与质量保证/质量控制 (QA/QC)。 美国马萨诸塞州米尔福德，2026年6月9日 - 沃特世公司（纽约证券交易所代码： WAT ）今天宣布推出专为变革电池安全测试而设计的WatersTM TA Instruments™ Coin Cell差示扫描量热仪（DSC）。这款仪器专为电池研发人员量身打造，可直接测试全组装纽扣电池，省去繁琐的前处理步骤，同时提供更快、更全面的安全与性能表征数据。 Waters TA Instruments Coin Cell差示扫描量热仪（DSC） Coin Cell DSC是目前市场上少有的能够实现多维数据采集的商用差示扫描量热仪 1 ，可在执行全电池热分析的同时，并行测量逸出气体与电化学性能。通过集成电压监测及充放电功能，研究人员可直接建立热行为与电化学行为之间的关联，从而更早获得关于热失控和电池失效的洞察。此外，该系统还可与质谱仪（MS）、傅里叶变换红外光谱仪（FTIR）或气相色谱-质谱系统（GC-MS）联用，直接分析逸出气体成分。 沃特世公司材料科学事业部研发与产品解决方案副总裁 Yu Cheng表示：“Coin Cell DSC是电池热分析领域的一项重大突破。并行采集热分析、逸出气体及电化学数据，不仅显著提升测试效率，更能在研发早期阶段精准关联同一样品多个维度的数据，获取更深入的见解。得益于宽泛的测试温度范围与精简的工作流程，该系统能降低实验复杂程度，在性能方面也优于现有测试方案。” Coin Cell DSC采用独特的胶囊式设计，省去了拆解电池这一耗时的操作步骤，平均样品制备时间缩短了90%以上 2 。这种设计在有效保护样品完整性的同时，大幅加快了数据获取速度。 这款全新系统兼具出众的温度性能、高效的工作流程与多维数据采集功能，重新定义了电池热分析的性能技术标准。Coin Cell DSC的测试温度范围覆盖–80至600 ℃ 3, 4 ，属业内前列水平，可全方位表征电池的低温与高温行为，拓展未来在研发和质量保证/质量控制 (QA/QC) 中的应用。

Faster run times for GLP-1 , insulin, and LNP drug substance testing accelerates biopharmaceutical development timelines and reduces production bottlenecks. Delivers up to 2x increase in resolving power and sensitivity to identify and track low-level impurities for improved regulatory readiness. Industry-first chemical and physical particle optimization delivers reproducible methods for increasingly complex biologics. MILFORD, Mass. , June 8, 2026 /PRNewswire/ -- 55th International Symposium on High Performance Liquid Phase Separations and Related Techniques—Waters Corporation (NYSE: WAT) today announced the launch of the BioResolve™ Peptide and GTxResolve™ Lipid Phenyl-Hexyl+ and C18+ Columns, a first-of-its-kind reversed-phase (RP) column platform designed to tackle a persistent biopharmaceutical challenge: reliably separating structurally and chemically similar impurities in GLP-1 peptides, insulin, and lipid nanoparticles (LNPs) to support the development of safe, effective drug products. In GLP-1 receptor agonists and newer mRNA-based therapies such as in vivo CAR T, difficulty resolving impurities can delay time to market, weaken regulatory confidence, and affect patient safety. Traditional RP columns do not always separate low-level or closely related impurities well, often requiring longer analyses, detector-suppressing mobile-phase additives, or repeated method redevelopment. BioResolve Peptide and GTxResolve Lipid Columns help to overcome these limitations with ready-to-use methods that improve both resolution 1,2 and speed 2,3 while fitting into existing workflows. "We have made simultaneous advances in both chemistry and particle physics to deliver the first columns Waters has introduced to market specifically QC batch-tested for GLP‑1 analysis 4 and lipid nanoparticles, 2 solving a longstanding customer pain point," said Erin Chambers, Vice President, General Manager, Consumables & Lab Automation, Waters Analytical Sciences, Waters Corporation. "BioResolve Peptide and GTxResolve Lipid Columns are designed to resolve chemically similar GLP‑1 impurities and LNP components faster when speed matters, 2,3 and with extraordinary resolution 1 when certainty is required. The result is simpler method development, regulatory‑ready data, 5 and faster, highly reproducible methods, ultimately helping to reduce cost burdens on important new therapeutics." BioResolve Peptide and

新闻摘要： 缩短GLP-1、胰岛素及LNP原料药检测运行时间，加速生物制药开发进程并减少生产瓶颈。 分辨率和灵敏度提升达2倍，可识别和追踪低水平杂质，提升法规合规准备度。 业内开创性化学与物理颗粒优化技术，为日益复杂的生物制品提供可重现的方法。 美国马萨诸塞州米尔福德，2026年6月8日 - 第55届高效液相分离及相关技术国际研讨会 - 沃特世公司（纽约证券交易所代码：WAT）今日宣布推出BioResolve™肽类及GTxResolve™脂质苯己基+（Phenyl-Hexyl+）和C18+色谱柱。这一业界创新的反相（RP）色谱柱平台专为攻克生物制药领域的一项长期难题而设计：能够可靠分离GLP-1肽、胰岛素及脂质纳米颗粒（LNP）中结构与化学性质极为相似的杂质，从而支持安全、有效的药物产品开发。 在GLP-1受体激动剂及新型mRNA疗法（如体内CAR T）的研发中，杂质分离困难往往会导致上市延迟、削弱监管机构的信心，并影响患者用药安全。传统反相色谱柱在分离低含量或结构高度相似的杂质时表现欠佳，通常需要更长的分析时间、依赖抑制检测器信号的流动相添加剂，或需反复重新开发方法。BioResolve肽类与GTxResolve脂质色谱柱凭借即用型方法，成功突破了上述局限，在兼容现有工作流程的同时，实现了分辨率 1,2 与分析速度 2,3 的同步提升。 沃特世公司分析科事业部副总裁兼消耗品与实验室自动化总经理Erin Chambers表示：“我们在化学填料与颗粒物理结构方面取得了双重突破，推出了沃特世首批专门针对GLP-1分析 4 及脂质纳米颗粒 2 进行质控（QC）批量检测认证的色谱柱，解决了客户长期以来的痛点。BioResolve肽类与GTxResolve脂质色谱柱旨在以更快的速度 2,3 分离化学性质相近的GLP-1杂质与LNP组分，并在需要确证性结果时提供出色的分辨率1。这不仅简化了方法开发，提供了合规性数据5，更为客户带来快速且具有高重现性的分析方法，最终有效降低重要新疗法的成本负担。” BioResolve肽类与GTxResolve脂质色谱柱采用特殊设计的表面化学与表面多孔颗粒技术，可针对这两类难分离样品提供高度准确的反相分离选择性。该系列色谱柱可提供苯己基+与C18+两种化学填料，采用230

FDA 510(k)-cleared BD BACTEC™ FXI Culture System now available to U.S. market, enabling broader access to confident bloodstream infection diagnostics. Achieves a 3-hour faster time to detection (~15% reduction) versus the prior-generation system, per clinical study data, enabling earlier targeted sepsis prevention. Fully automated solution delivers an industry-leading 50% increase in vial loading and up to 960-vial per module capacity, maximizing walk-away time. MILFORD, Mass. , June 3, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced that the BD BACTEC FXI Culture System has received U.S. Food and Drug Administration (FDA) 510(k) clearance. This clearance enables commercialization in the U.S. and provides a new option for laboratories seeking a fully automated blood culture system designed to improve the speed, consistency, and accuracy of sepsis and bloodstream infection diagnostics in modern microbiology laboratories. Clinical study data¹ showed that the BD BACTEC FXI Culture System reduced mean time to detection by approximately three hours (~15%) compared with the previous-generation BD BACTEC™ FX Blood Culture System (17 hours vs. 20 hours). Faster detection enables earlier pathogen identification and more timely targeted antimicrobial therapy for patients with suspected bloodstream infections and sepsis. Because each hour of delayed sepsis treatment increases mortality by 3.6% to 9.9%, 2 faster diagnostic workflows are critical in acute care settings. "Recent evidence-based laboratory guidelines document the beneficial clinical impact of rapid laboratory results for the detection of bloodstream infections; therefore, advancing the science of automated blood culture instruments is critical to further speed results," said Donna M. Wolk, MHA, Ph.D., D(ABMM), Division Chief, Molecular and Microbial Diagnostics and Development, Geisinger Medical Laboratories. "Reducing the time to detection for positive results is key to improving the availability of Gram stain and other tests, on which treatment decisions are based. The faster, the better." The BD BACTEC FXI Culture System features a first-of-its-kind capability in a blood culture platform – an automated gravimetric measurement of individual blood culture vial volume. By objectively confirming blood volume in each vial, the system reduces pre-analytical variability and supports more consistent diagnostics and adherence to recommended collection practices. "Waters is proud to bring the BD BACTEC FXI Culture System to the U.S. market, delivering an important advancement in bloodstream infection diagnostics," said Jianqing Bennett, Senior Vice President, W

Delivers up to 20x improvement in MS/MS sensitivity and 2x faster acquisition speeds, enabling deeper biological insight for next-generation multiomics, therapeutic, and high-throughput workflows. Identifies up to 40% more lipids by LC‑MS/MS than the leading alternative benchtop high‑resolution mass spectrometer, advancing lipidomics research and disease understanding. Sets a new benchmark for throughput in high-resolution spatial analysis with the DESI XS source, supporting higher-confidence studies of disease and treatment response. MILFORD, Mass. , June 1, 2026 /PRNewswire/ -- 74 th ASMS Conference on Mass Spectrometry and Allied Topics—Waters Corporation (NYSE: WAT) today introduced the Waters Xevo™ MRT P10 Mass Spectrometer , a high-resolution Quadrupole Time-of-Flight (QToF) System for high-throughput multiomics, bioanalysis, and biopharmaceutical laboratories. The Xevo MRT P10 MS delivers up to 20x higher MS/MS sensitivity compared to its predecessor, along with industry-leading speed and expanded acquisition modes to comprehensively support both targeted and untargeted analysis in a single benchtop platform. The system is designed to accelerate biomarker discovery and validation while supporting the identification of disease pathways and therapeutic targets across large-cohort biomedical research and epidemiology studies. "With the Xevo MRT P10 MS, we are raising the standard for benchtop high-resolution mass spectrometry," said James Hallam, Vice President & General Manager, Liquid Chromatography-Mass Spectrometry, Waters Analytical Sciences, Waters Corporation. "By combining enhanced MS/MS sensitivity, the industry's fastest benchtop acquisition speeds, and advanced intelligent acquisition modes in LC-MS/MS – and layering in a new benchmark for MS imaging speed and throughput with our DESI XS – this platform empowers researchers to see more biology, accelerate discovery, and make confident decisions. The Xevo MRT P10 MS represents a powerful step forward for our customers working to advance multiomics research and life‑changing therapies." As researchers pursue deeper analytical insights, they face a bottleneck: generating high quality MS/MS information at the speed required by modern workflows. The Xevo MRT P10 MS is engineered to solve that problem. It offers up to 20× gre

>10x step-change in MS/MS sensitivity paired with multipass Cyclic™ Ion Mobility Spectrometry (IMS) reveals subtle biological differences for earlier, previously unattainable detection of disease signals. 50% extended upper mass range and comprehensive suite of structural tools advance the development of next-generation biotherapeutics. Integrated MALDI XS and DESI XS imaging with high-resolution ion mobility enables direct visualization of molecules in tissue, improving understanding of how disease develops at the cellular level. MILFORD, Mass. , June 1, 2026 /PRNewswire/ -- 74 th ASMS Conference on Mass Spectrometry and Allied Topics— Waters Corporation (NYSE: WAT) today announced the launch of the Waters Cyclic IMS P20 Mass Spectrometer , a high-resolution structural and spatial omics platform designed to help scientists see biology more clearly, and act on it faster. Combining multipass Cyclic Ion Mobility Spectrometry with an enhanced suite of fragmentation, probing, and imaging capabilities , this unique and powerful instrument delivers confident insights for the early detection of disease signals, from protein misfolding to post-translational modifications. The system's full‑spectrum molecular imaging unlocks unparalleled visualization within a single experiment 1 to accelerate discovery and development, and power deeper understanding of complex biology. "Waters recognizes that advanced tools for structural and spatial omics play a critical role in delivering therapeutic breakthroughs," said James Hallam, Vice President & General Manager, Liquid Chromatography-Mass Spectrometry, Waters Analytical Sciences, Waters Corporation. "With its powerful fusion of capabilities, the Cyclic IMS P20 MS delivers a previously unattainable view into subtle molecular differences, unlocking a new level of understanding of the mechanisms that drive disease and advancing next‑generation discovery." As researchers pursue larger and more heterogeneous therapeutic targets, analytical workflows need higher sensitivity, higher structural resolution, and easier-to-adopt methods

新闻摘要 ： MS/MS灵敏度提升逾10倍，结合多循环环形离子淌度谱（Cyclic™ IMS），可揭示细微的生物学差异，更早甄别疾病信号，突破以往的检测局限 1 。 量范围上限扩展50%以上，结合全面的结构分析工具助力新一代生物治疗药物开发 2 。 集成MALDI XS和DESI XS成像离子源，结合高分辨率离子淌度技术，可实现组织中分子的全面可视化，有助于深入探索疾病在细胞水平的发生机制 3 。 美国马萨诸塞州米尔福德，2026年6月1日 - 第74届美国质谱年会（ASMS）- 沃特世公司（纽约证券交易所代码：WAT）今日隆重推出 Waters TM Cyclic TM IMS P20高分辨质谱仪 ，用于结构生物学和空间组学等领域的研究，旨在帮助科学家更清晰地洞察生物学本质，更高效地将发现转化为行动。该仪器将环形离子淌度质谱技术与一系列增强型碎裂、电离和成像模式深度融合，不仅设计新颖，而且功能强大，能够为疾病信号的早期检测提供可靠的科学依据，广泛适用于蛋白质错误折叠到翻译后修饰等应用场景。该系统搭载全谱分子成像功能，可通过单次实验实现出色的可视化效果，突破了以往的技术局限1，能够加速药物发现和开发进程，助力科研人员深入解析复杂生物学机制。 Waters Cyclic IMS P20 质谱仪将多循环离子淌度谱技术与增强型碎裂、电离和成像模式融合，能够揭示细微的生物学差异，获得对疾病信号更早、更精确、此前难以实现的检测。 沃特世公司分析科学事业部液相色谱-质谱副总裁兼总经理James Hallam表示：“沃特世深知，先进的结构生物学和空间组学研究工具，是推动治疗药物取得突破性成果的关键驱动力。凭借强大的多维功能融合，Cyclic IMS P20 质谱仪能够以全新视角揭示分子的细微差异，将科研人员对疾病驱动机制的认知提升至全新高度，有力推动新一代药物的发现进程。” 随着研究人员不断探索更大、异质性更高的治疗靶点，分析工作流程对灵敏度、结构分辨率和方法易用性的要求也越来越高。Cyclic IMS P20质谱仪正是为此而生：与上一代产品相比，其MS/MS灵敏度跃升逾10倍2，质量范围上限扩展50%以上，超过了100

MILFORD, Mass. , May 18, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3rd, 2026, at 10:30 AM Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at https://ir.waters.com . A replay of the webcast will be available for 90 days. About Waters Corporation Waters Corporation (NYSE:WAT) is a global leader in life sciences, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with analytical laboratories around the world to advance the release of effective, high-quality medicines, assure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combatting growing antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of approximately 16,000 employees partner with our customers to turn scientific challenges into breakthroughs that improve lives worldwide. Caspar Tudor, Head of Investor Relations [email protected] View original content: https://www.prnewswire.com/news-releases/waters-corporation-to-present-at-the-jefferies-global-healthcare-conference-302775033.html SOURCE Waters Corporation

MILFORD, Mass. , April 20, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q1 2026 financial results conference call on Tuesday, May 5, 2026 at 8:30 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com . A replay of the webcast will also be available until at least June 2, 2026, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~16,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide. For more information, please visit www.waters.com/about . Caspar Tudor, Head of Investor Relations [email protected] View original content: https://www.prnewswire.com/news-releases/waters-corporation-schedules-first-quarter-2026-earnings-conference-call-302747613.html SOURCE Waters Corporation

色谱运行时间可缩短至原来的四分之一，从而加速在发现、开发及质量控制工作流程中的决策 1,3 。 绝对摩尔质量测量精度和尺寸测定范围提升10倍，且不影响分辨率或分析通量 2 。 样品用量减少30%-50%，溶剂用量减少约40% 3 。 美国马萨诸塞州米尔福德，2026年4月14日——沃特世公司（纽约证券交易所代码：WAT）今日重磅推出Waters™ omniDAWN多角度光散射(MALS) 分析系统，属于旗下怀雅特产品系列。这款分析系统具有18个检测角度，是一款适用于超效液相色谱(UHPLC)和超高效液相色谱(UPLC)工作流程的宽范围MALS分析系统，可在不牺牲分离度或通量的前提下测量分子的绝对摩尔质量和尺寸。 Waters omniDAWN多角度光散射(MALS) 分析系统 omniDAWN MALS分析系统将兼容UPLC的MALS尺寸测定范围扩大了10倍，测量半径从约50 nm扩展至500 nm，从而能够可靠地表征更大、更复杂的分析物，如蛋白质聚集体、病毒载体、脂质纳米颗粒(LNP)和先进材料。由于能够测定绝对摩尔质量和尺寸，omniDAWN分析系统减少了对色谱柱校准标准品的依赖，帮助用户更快获得结果并进行更可靠的对比，从而简化生物类似药研究、抗体偶联药物(ADC)表征和病毒载体分析等工作流程。随着这些药物和其他先进疗法进入开发后期和质量控制阶段，实验室越来越依赖UHPLC和UPLC系统来满足不断提高的通量和分离度要求。 沃特世公司分析科学高级副总裁Rob Carpio表示：“针对复杂生物制剂及新型疗法的UHPLC和UPLC分离技术发展迅速，但检测技术一直未能跟上步伐，这一局面如今被打破。omniDAWN MALS分析系统将宽范围多角度光散射检测技术引入现代分离体系，使我们的客户能够更快地推进工作，同时保持表征所需的分离度、稳定性和深度，从而加速新一代疗法的发现、开发和质量控制进程。” omniDAWN分析系统可与Waters UPLC系统及色谱柱无缝集成，相比传统技术，在系统扩散、稳定性与分析性能之间实现了良好平衡，为多属性表征提供了完善的解决方案。与微量MALS方法相比，这款产品在易用性方面也展现出优势 2

Delivers up to 4x faster chromatographic run times to accelerate decisions across discovery, development, and quality workflows. 1,3 Achieves 10x improvement in absolute molar mass and extended sizing, without compromising resolution or analytical throughput. 2 Reduces sample consumption by 30-50% and solvent use by approximately 40%. 3 MILFORD, Mass. , April 14, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced the launch of the Waters omniDAWN™ Multi-Angle Light Scattering (MALS) Photometer, part of the Wyatt Technology Portfolio. Featuring 18 angles of detection, the omniDAWN Photometer is the first extended-range MALS detector for Ultra High Performance Liquid Chromatography (UHPLC) and Ultra Performance Liquid Chromatography (UPLC) workflows, delivering absolute molar mass and size measurements without compromising resolution or throughput. The omniDAWN MALS Photometer extends UPLC-compatible sizing ten-fold, from approximately 50 to 500 nm in radius, enabling reliable characterization of larger, more complex analytes such as protein aggregates, viral vectors, lipid nanoparticles (LNPs), and advanced materials. Because it provides absolute molar mass and size, the omniDAWN Photometer reduces reliance on column calibration standards and supports faster results and more confident comparisons, streamlining work across biosimilarity studies, antibody-drug conjugate (ADC) characterization, and viral vector analytics. As these modalities and other advanced therapeutics move into late-stage development and quality control, laboratories increasingly rely on UHPLC and UPLC Systems to meet rising throughput and resolution requirements. "Advances in UHPLC and UPLC separations for complex biologics and newer modalities have outpaced detector technology, until now," said Rob Carpio, Senior Vice President, Waters Analytical Sciences, Waters Corporation. "The omniDAWN MALS Photometer brings extended-range multi-angle light scattering to modern separations. This means our customers can move faster while maintaining the resolution, robustness, and depth of characterization needed to accelerate the discovery, development, and quality control of next-generation therapies." Integrating seamlessly with Waters UPLC Systems and columns, the omniDAWN Photometer eliminates traditional trade-offs between dispersion, robustness, and analytical performance, delivering a complete solution for multi-attribute characterization with improved usability 2 compared to micro‑volume MALS approaches. When paired with UHPLC or UPLC Systems, the omniDAWN Photometer supports run times up to four times faster than conventional HPLC workflows, while reducing sample consumption by 30–50% and solvent use b

FDA-approved BD Onclarity™ HPV Assay is the most comprehensive screening tool for HPV in the U.S. 1,4 with extended genotyping and end-to-end automated lab workflows. At-home self-collection reduces significant barriers for unscreened or under-screened individuals who make up approximately 60% of cervical cancer cases. 3 Waters is establishing partnerships to enable broader nationwide access to the Onclarity™ HPV Self-Collection Kit for patients and prescribers to reduce cervical cancer risk. Waters Corporation (NYSE: WAT) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping for at-home use, marking a significant milestone in expanding access to cervical cancer screening, and removing barriers that currently prevent many individuals from receiving routine screening. Cervical cancer is largely preventable with regular screening and early detection of human

Waters Corporation (NYSE: WAT) (the "Company" or "Waters") today announced that it has priced an offering (the "Offering") of $3.5 billion aggregate principal amount of the following senior notes issued by its subsidiary, Augusta SpinCo Corporation ("Augusta"): $650 million aggregate principal amount of 4.321% Senior Notes due 2027 at the issue price of 100.000% of their principal amount; $600 million aggregate principal amount of 4.398% Senior Notes due 2029 at the issue price of 100.000% of their principal amount; $750 million aggregate principal amount of 4.656% Senior Notes due 2031 at the issue price of 100.000% of their principal amount; $750 million aggregate principal amount of 4.945% Senior Notes due 2033 at the issue price of 100.000% of their principal amount; and $750 million aggregate principal amount of 5.245% Senior Notes due 2036 at the issue price of 100.000% of their principal amount (collectively, the "Notes"). The Offering is expected to close on or about March 23,

沃特世旗舰新品ARES-G3流变仪以突破性速度树立数据质量新标杆 新闻摘要 ： 将标准检测时间缩短80%。 1 实现业界前沿的每秒25,000个数据点采集能力，可捕捉以往难以测量的瞬态材料行为。 2 校准需求更少，具备优异的气氛和温度控制性能。 3 得克萨斯州圣安东尼奥市与马萨诸塞州米尔福德市，2026年3月9日，Pittcon展会 — 沃特世公司（纽约证券交易所代码：WAT）今日重磅推出TA仪器产品线新品 ARES-G3TM流变仪 。该新一代流变仪可提供业内出色的分析速度与数据质量，加速材料研究和产品开发进程。ARES-G3流变仪凭借完全集成的“快速频率调制”（Fast Frequency Chirps）技术，每秒可采集多达25,000个数据点（较前代提升10倍），并将标准检测时间缩短多达80%，有效突破了行业瓶颈。随着科研人员和材料创新人员不断探索对复杂材料行为的更深层理解，这款产品为聚合物及复合材料开发、液态及半液态涂层以及基础研究领域解锁了全新的能力和成果。 沃特世公司材料科学事业部高级副总裁Dan Rush表示：“流变学实验室正承受巨大压力，需要更快提供更优质的数据，以推动突破性进展并支持业务决策。我们很高兴能推出这款先进的仪器，它能在创纪录的时间内提供独特数据，赋予客户全新洞察力，帮助应对日益增长的需求。” ARES-G3流变仪可缩短实验时间、提升实验室通量，并能在单次测试中获得以往难以获取的快速变化样品的数据。该仪器通过增强版TRIOSTM软件全面集成 “快速频率调制”解决方案，无需多份软件许可证和高级编程包培训，即可通过快速频率扫描来捕获和处理数据。常规质量控制测试和数据生成也比以前提速80%，部分测试的时长可从6小时缩短到1小时；这意味着在常规条件下，工作流程得以加速，每年可为团队节省数百个工作日，且数据质量不受影响。ARES-G3流变仪还能够在无需用户校准的情况下执行多项测试，有效减少人为误差，增强测量结果的可靠性。 明尼苏达大学化工与材料科学系名誉教授Chris

Pittcon 2026 Conference + Exposition - Waters Corporation (NYSE: WAT) today launched the ARES-G3™ Rheometer , part of the TA Instruments product line. This next-generation rheometer delivers industry-leading speed paired with best-in-class data to accelerate materials research and product development. Capturing up to 25,000 data points per second (10x more than its predecessor) and cutting standard test times by up to 80% through fully integrated Fast Frequency Chirps, the ARES-G3 Rheometer addresses pressing industry limitations. As scientists and materials innovators pursue a deeper understanding of complex material behavior, this product unlocks new capabilities and outcomes across polymer and composites development, liquid and semi-liquid coatings, and fundamental research. "Rheology labs are under enormous pressure to deliver better data, faster, to unlock breakthroughs and support business decisions," said Dan Rush, Senior Vice President, Waters Materials Sciences, Waters

新闻提要： 灵敏度可达不锈钢微流柱的2倍以上，有助于高通量生物分离、DMPK和组学应用降低检测限和定量限 1 。 相较于传统2.1 mm内径色谱柱，可降低多达75%的样品用量。有效节约细胞与基因疗法及个性化医疗候选药物等宝贵样品，同时提供更深入的数据洞察 2 。 溶剂消耗量仅为2.1 mm内径色谱柱的四分之一，助力实验室实现可持续发展目标、降低运营成本并加快检测进程，分析性能丝毫不受影响 2 。 美国马萨诸塞州米尔福德 ——近日，沃特世公司（纽约证券交易所代码：WAT）宣布旗下ACQUITY™、BioResolve™和GTxResolve™液相色谱柱系列新增 1 mm内径微流柱规格 ，均采用 Waters MaxPeak™ Premier技术。新推出的这几款微流柱不仅大幅提升了检测灵敏度，还能有效避免溶剂和样品浪费，在生物分析、药物发现与开发，以及代谢组学、蛋白组学及脂质组学等样品宝贵、时间紧迫的领域，均能获得高质量的分析结果。 此次新品发布延续了公司在高影响力化学创新方面的强劲势头，通过突破现有技术瓶颈，重新定义了在分离更大、更复杂分子方面的可能性。 沃特世分析科学高级副总裁Rob Carpio表示：“沃特世持续投入突破性技术的研发，为高通量制药和生物制药实验室的客户消除障碍，助力他们加速并简化研发进程，让挽救生命的疗法早日惠及患者。我们深知，在细胞与基因疗法、个性化癌症药物等领域，样品量往往十分有限，因此分析物的回收率至关重要。沃特世此次重磅推出多款采用MaxPeak Premier技术的新型微流液相色谱柱，不仅能有效保护这些珍贵的样品，还将分析的灵敏度、数据质量和重现性提升至全新高度。” 新推出的微流LC色谱柱将沃特世MaxPeak高性能表面(HPS)技术应用于1 mm内径规格。这一重大技术突破尽可能降低了非特异性吸附(NSA)，并显著提高了小分子、多肽及寡核苷酸的回收率。通过消除分析障碍并加速工作流程，MaxPeak HPS技术能够为研究磷酸化肽等难以提升回收率的客户带来极大助益。 加州大学戴维斯分校教授Oliver Fiehn博士表示：“将内径2.1 mm的不锈钢色谱柱换成采用Waters MaxPeak Premier技术的色谱柱之后，我们发现分析灵敏度完全能达到要求，甚至更加出色！很高兴看到MaxPeak技术如今扩展至1

Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the TD Cowen Health Care Conference on Monday, March 2nd, 2026, at 11:10 AM Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at https://ir.waters.com . A replay of the webcast will be available for 90 days. About Waters Corporation Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive

Waters Corporation (NYSE: WAT) today launched 1 mm I.D. liquid chromatography (LC) columns with Waters' MaxPeak™ Premier Technology for its ACQUITY™, BioResolve™, and GTxResolve™ Column brands. Significantly improving sensitivity while minimizing solvent and sample waste, the new microflow columns deliver high-quality results across bioanalysis, pharmaceutical discovery and development, and metabolomics, proteomics and lipidomics – all areas where both sample availability and time are limited. This launch builds on the Company's strong cadence of high-impact chemistry innovation, redefining what is possible in the separation of larger, more complex molecules by exceeding the limits of current technologies. "Waters continues to invest in the advancement of breakthrough technologies to remove common obstacles for our customers in high-throughput pharmaceutical and biopharmaceutical laboratories, accelerating and simplifying the development of life-changing therapies," said Rob Carpio,

Announces appointment of Claire M. Fraser, Ph.D., to its Board of Directors Forms a global life sciences and diagnostics leader focused on high-volume testing in regulated applications Announces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences Waters Corporation (NYSE: WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE: BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies, and an industry-leading financial outlook. The Company also announced the appointment of Claire M. Fraser, Ph.D., to its Board of Directors (the "Waters Board"), increasing the size of the Waters Board to a total of 11 members. Dr. Fraser is a globally acclaimed genome scientist, with three decades of experience managing large